AVTX-010 / Avalo Therap - LARVOL DELTA

Avalo Therapeutics…announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders (GlobeNewswire) - "AVTX-010 is an engineered anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart....The Company expects to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027."

IND • Pipeline update • Hidradenitis Suppurativa • Inflammation